Literature DB >> 19251937

Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity.

Sergio A Dromi1, Meghaan P Walsh, Sarah Herby, Bryan Traughber, Jianwu Xie, Karun V Sharma, Kiran P Sekhar, Alfred Luk, David J Liewehr, Matthew R Dreher, Terry J Fry, Bradford J Wood.   

Abstract

PURPOSE: To evaluate the influence of subtotal radiofrequency (RF) ablation on a tumor-specific immune response in a murine tumor model and to explore the role of intratumoral dendritic cells (ITDCs) in mediating this effect.
MATERIALS AND METHODS: Animal work was performed according to an approved protocol and in compliance with the National Cancer Institute Animal Care and Use Committee guidelines and regulations. A murine urothelial carcinoma (MB49) model expressing the male minor histocompatibility (HY) antigen was inoculated subcutaneously in female mice. Fourteen days later, splenic T cells were analyzed with enzyme-linked immunosorbent spot for HY immune response (n = 57). In subsequent experiments, mice were randomized into control (n = 7), RF ablation, ITDC (n = 9), and RF ablation + ITDC (n = 9) groups and monitored for tumor growth. Eleven days after treatment, tumors were harvested for histologic and immunohistochemical analysis. Animals demonstrating complete tumor regression were rechallenged in the contralateral flank.
RESULTS: Animals treated with subtotal RF ablation showed significant increases in tumor-specific class I and II responses to HY antigens and tumor regression. RF ablation, ITDC, and combined groups demonstrated similar levels of antigen-presenting cell infiltration; all groups demonstrated greater levels of infiltration compared with untreated controls. ITDC injection also resulted in tumor regression. However, combination therapy did not enhance tumor regression when compared with either treatment alone. Rechallenged mice in RF ablation, ITDC, and combination groups demonstrated significant tumor growth inhibition compared with controls.
CONCLUSION: Subtotal RF ablation treatment results in enhanced systemic antitumor T-cell immune responses and tumor regression that is associated with increased dendritic cell infiltration. ITDC injection mimics the RF ablation effect but does not increase immune responses when injected immediately after RF ablation.

Entities:  

Mesh:

Year:  2009        PMID: 19251937      PMCID: PMC2663580          DOI: 10.1148/radiol.2511072175

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  28 in total

Review 1.  Dendritic cell immunotherapy: mapping the way.

Authors:  Carl G Figdor; I Jolanda M de Vries; W Joost Lesterhuis; Cornelis J M Melief
Journal:  Nat Med       Date:  2004-05       Impact factor: 53.440

2.  Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.

Authors:  Fraia Melchionda; Terry J Fry; Matthew J Milliron; Melissa A McKirdy; Yutaka Tagaya; Crystal L Mackall
Journal:  J Clin Invest       Date:  2005-04-07       Impact factor: 14.808

Review 3.  High-intensity focused ultrasound in the treatment of solid tumours.

Authors:  James E Kennedy
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

4.  Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation.

Authors:  Feng Wu; Zhi-Biao Wang; Pei Lu; Zhong-Li Xu; Wen-Zhi Chen; Hui Zhu; Cheng-Bing Jin
Journal:  Ultrasound Med Biol       Date:  2004-09       Impact factor: 2.998

Review 5.  Arrhenius relationships from the molecule and cell to the clinic.

Authors:  W C Dewey
Journal:  Int J Hyperthermia       Date:  1994 Jul-Aug       Impact factor: 3.914

Review 6.  Tumor destruction and in situ delivery of antigen presenting cells promote anti-neoplastic immune responses: implications for the immunotherapy of pancreatic cancer.

Authors:  Patrizia Rovere-Querini; Angelo A Manfredi
Journal:  JOP       Date:  2004-07

7.  Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits.

Authors:  Thaddäus Till Wissniowski; Johannes Hänsler; Daniel Neureiter; Markus Frieser; Stefan Schaber; Birgit Esslinger; Reinhard Voll; Deike Strobel; Eckhart G Hahn; Detlef Schuppan; Thädaus Till Wissniowski; Johannes Hünsler
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

8.  Escape from immune surveillance does not result in tolerance to tumor-associated antigens.

Authors:  Fraia Melchionda; Melissa K McKirdy; Filomena Medeiros; Terry J Fry; Crystal L Mackall
Journal:  J Immunother       Date:  2004 Sep-Oct       Impact factor: 4.456

9.  In situ tumor ablation creates an antigen source for the generation of antitumor immunity.

Authors:  Martijn H M G M den Brok; Roger P M Sutmuller; Robbert van der Voort; Erik J Bennink; Carl G Figdor; Theo J M Ruers; Gosse J Adema
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

10.  Molecular identification of a danger signal that alerts the immune system to dying cells.

Authors:  Yan Shi; James E Evans; Kenneth L Rock
Journal:  Nature       Date:  2003-09-07       Impact factor: 49.962

View more
  71 in total

Review 1.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

2.  Science to practice: Can we expand focal interventional oncologic ablation treatments into an effective systemic therapy?

Authors:  S Nahum Goldberg
Journal:  Radiology       Date:  2013-05       Impact factor: 11.105

Review 3.  Current status and perspectives of immune-based therapies for hepatocellular carcinoma.

Authors:  Maridi Aerts; Daphné Benteyn; Hans Van Vlierberghe; Kris Thielemans; Hendrik Reynaert
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 4.  Thermal ablation of tumours: biological mechanisms and advances in therapy.

Authors:  Katrina F Chu; Damian E Dupuy
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

Review 5.  Combined locoregional-immunotherapy for liver cancer.

Authors:  Tim F Greten; Michal Mauda-Havakuk; Bernd Heinrich; Firouzeh Korangy; Bradford J Wood
Journal:  J Hepatol       Date:  2019-02-07       Impact factor: 25.083

6.  Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation.

Authors:  Sebastian P Haen; Cécile Gouttefangeas; Diethard Schmidt; Andreas Boss; Stephan Clasen; Alexandra von Herbay; Bora Kosan; Hermann Aebert; Philippe L Pereira; Hans-Georg Rammensee
Journal:  Cell Stress Chaperones       Date:  2011-03-26       Impact factor: 3.667

7.  Pre-resectional Radiofrequency Ablation as a Neoadjuvant in situ Tumor Vaccine.

Authors:  Fumito Ito; Sharon S Evans
Journal:  J Vaccines Vaccin       Date:  2016-03-09

8.  Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors.

Authors:  Madhava Pai; Nagy Habib; Hakan Senturk; Sundeep Lakhtakia; Nageshwar Reddy; Vito R Cicinnati; Iyad Kaba; Susanne Beckebaum; Panagiotis Drymousis; Michel Kahaleh; William Brugge
Journal:  World J Gastrointest Surg       Date:  2015-04-27

9.  The use of radiofrequency ablation in pancreatic cancer in the midst of the dawn of immuno-oncology.

Authors:  Isabella Reccia; Jayant Kumar; Nagy Habib; Mikael Sodergren
Journal:  Med Oncol       Date:  2018-10-04       Impact factor: 3.064

10.  Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results.

Authors:  Mirko D'Onofrio; Stefano Crosara; Riccardo De Robertis; Giovanni Butturini; Roberto Salvia; Salvatore Paiella; Claudio Bassi; Roberto Pozzi Mucelli
Journal:  Technol Cancer Res Treat       Date:  2016-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.